FDA Adds Bladder Cancer Warnings to Takeda ' s Actos

The U.S. FDA has concluded that use of Takeda ' s Actos (pioglitazone), a type 2 diabetes medicine, may be linked to an increased risk of bladder cancer and has approved label updates.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news